Alendon 70mg Tablet 10's strip

Alendon 70mg Tablet 10's strip
৳ 250.33/=
Ex Tax: ৳ 250.33/=
- Stock: In Stock
- Model: MEDI-00125
- Generic: Alendronic acid
- Pack Size: Each pack contains 10 pcs. of Alendon 70mg tablet
0 items sold
4333 views
Available Options
Indications
Alendronic acid is indicated for the-
- Treatment and prevention of osteoporosis in post-menopausal women
- Treatment of osteoporosis, Alendronic acid increases bone mass and reduces the incidence of fractures, including those of the hip and spine (vertebral compression fractures)
- Prevention of osteoporosis, Alendronic acid may be considered in postmenopausal women who are at risk of developing osteoporosis and for whom the desired clinical outcome is to maintain bone mass and to reduce the risk of future fracture
- Treatment toincrease bone mass in men with osteoporosis
- Treatment of glucocorticoid-induced osteoporosis in men and women receiving glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and who have low bone mineral density. Patients treated with glucocorticoids should receive adequate amounts of calcium and vitamin D
- Treatment of Paget’s disease of bone in men and women
Therapeutic Class
Bisphosphonate preparations
Pharmacology
Alendronic acid inhibits osteoclast-mediated bone-resorption. Like all bisphosphonates, it is chemically related to inorganic pyrophosphate, the endogenous regulator of bone turnover. But while pyrophosphate inhibits both osteoclastic bone resorption and the mineralization of the bone newly formed by osteoblasts, alendronate specifically inhibits bone resorption without any effect on mineralization at pharmacologically achievable doses. Its inhibition of bone-resorption is dose-dependent and approximately 1,000 times stronger than the equimolar effect of the first bisphosphonate drug, etidronate. Under therapy, normal bone tissue develops, and alendronate is deposited in the bone-matrix in a pharmacologically inactive form. For optimal action, enough calcium and vitamin D are needed in the body in order to promote normal bone development. Hypocalcemia should, therefore, be corrected before starting therapy.
Dosage & Administration
Treatment of osteoporosis in post-menopausal women: The recommended dose is one Alendronic acid 70 mg once weekly or 10 mg once daily.
Treatment to increase bone mass in men with osteoporosis: The recommended dose is one Alendronic acid tablet 10 mg once daily. Alternatively, one Alendronic acid 70 mg once weekly may be considered.
Prevention of osteoporosis in post-menopausal women: The recommended dose is 35 mg once weekly or 5 mg once daily. The safety of treatment and prevention of osteoporosis with Alendronic acid has been studied for up to 7 years.
Use for elderly patients: No dosage adjustment is required for elderly patients. Because in clinical study there was no evidence of age related differences in the efficacy or safety profiles of Alendronic acid.
Treatment of glucocorticoid-induced osteoporosis in men and women: The recommended dose is 5 mg once daily, except for post-menopausal women not receiving oestrogen, for whom the recommended dose is 10 mg once daily.
Paget’s disease of bone in men and women: The recommended treatment regimen is 40 mg once a day for six months.
Treatment to increase bone mass in men with osteoporosis: The recommended dose is one Alendronic acid tablet 10 mg once daily. Alternatively, one Alendronic acid 70 mg once weekly may be considered.
Prevention of osteoporosis in post-menopausal women: The recommended dose is 35 mg once weekly or 5 mg once daily. The safety of treatment and prevention of osteoporosis with Alendronic acid has been studied for up to 7 years.
Use for elderly patients: No dosage adjustment is required for elderly patients. Because in clinical study there was no evidence of age related differences in the efficacy or safety profiles of Alendronic acid.
Treatment of glucocorticoid-induced osteoporosis in men and women: The recommended dose is 5 mg once daily, except for post-menopausal women not receiving oestrogen, for whom the recommended dose is 10 mg once daily.
Paget’s disease of bone in men and women: The recommended treatment regimen is 40 mg once a day for six months.
Interaction
The incidence of upper gastrointestinal side effects are increased with the concomitant use of non-steroidal anti-inflammatory agents and aspirin. Absorption of Alendronate is reduced in the presence of antacids and calcium supplements.
Contraindications
Hypocalcaemia; Renal impairment; Vitamin D deficiency; Active gastrointestinal problem such as dysphagia, oesophago-duodenitis or ulcer; and Hypersensitivity to any components of the tablet.
Side Effects
The commonest symptomatic side effects are constipation, diarrhoea, oesophageal ulcer, flatulence, dysphagia, musculoskeletal pain, headache, rarely rash, erythema, transient decrease in serum calcium and phosphate, nausea, vomiting, peptic ulceration, hypersensitivity reactions including urticaria and angio-oedema.
Pregnancy & Lactation
Alendronic acid should not be given to pregnant women or nursing mother.
Use in Special Population
Children: Not recommended.
Source: medex.com.bd